The document discusses malaria, which infects hundreds of millions annually and kills over 1 million people per year, mostly in Africa. It outlines the challenges in developing an effective malaria vaccine, including the parasite's ability to evade the immune system and lack of animal models for testing. Several past and current vaccine candidates are mentioned, including SPf66 (the first field trial vaccine), RTS,S (the most advanced candidate to date), and PfSPZ Vaccine (a whole parasite vaccine showing promise in recent trials). Overall, the document reviews the state of malaria vaccine research and the hurdles remaining in developing a highly effective vaccine.
No commercially available malaria vaccine at the present time.
RTS,S/AS01 is the most advanced vaccine candidate against malaria.
Commonest infectious disease in the tropics
200 millions per year affected with malaria
3 millions per year die due to malaria
A malaria vaccine is a vaccine that is used to prevent malaria. The only approved vaccine as of 2015 is RTS,S, known by the trade name Mosquirix. It requires four injections and has a relatively low efficacy.
No commercially available malaria vaccine at the present time.
RTS,S/AS01 is the most advanced vaccine candidate against malaria.
Commonest infectious disease in the tropics
200 millions per year affected with malaria
3 millions per year die due to malaria
A malaria vaccine is a vaccine that is used to prevent malaria. The only approved vaccine as of 2015 is RTS,S, known by the trade name Mosquirix. It requires four injections and has a relatively low efficacy.
RTS,S/AS01 (RTS,S) is a malaria vaccine that has been developed through a partnership between GlaxoSmithKline Biologicals (GSK) and the PATH Malaria Vaccine Initiative (MVI), with support from the Bill & Melinda Gates Foundation and from a network of African research centers that performed the studies.
vaccine is a biological preparation that provides active acquired immunity to a particular disease. A vaccine typically contains an agent that resembles a disease-causing microorganism and is often made from weakened or killed forms of the microbe, its toxins, or one of its surface proteins. The agent stimulates the body's immune system to recognize the agent as a threat, destroy it, and to further recognize and destroy any of the microorganisms associated with that agent that it may encounter in the future.
HISTORY OF VACCINES-
EDWARD JENNER conduct experiments in 1796 that lead to the creation of the first smallpox vaccine for prevention of smallpox.
A vaccine for RABIES is developed by LOUIS PASTEUR .
Vaccine for COLERA and TYPHOID were developed in 1896 and PLAGE vaccine in 1887.
The first DIPHTHERIA vaccine is developed in about 1913 by EMIL ADOLPH BEHRING,WILLIAM HALLOCK PARK.
The whole cell PERTUSIS vaccines are developed in 1914.
A TETANUS vaccine is developed in 1927.
Developing vaccines against infectious and epidemic diseases with the aid of Bioinformatics is now possible, by predicting epitopes on an antigen and finding possible targets for the antibody to bind. A new era of vaccine production is just ahead of us.
Watch out the ppt to know more!!!
phage therapy is the use of bacteriophages to kill pathogenic bacterial cells. Bacteriophages are bacterial parasites that invade bacterial cells and engulf them like blue whale fish kills euphausiids and copepodsand in sea .
Katie Flanagan - Malaria vaccines current status and challengesWAidid
Vaccines are considered the most cost-effective means of control, prevention, elimination, eradication of infectious diseases: for this reason, a malaria vaccine would greatly assist in the drive to eradicate malaria from the world. Professor Flanagan presents in this slideset the current status and challenges of developing malaria vaccines.
To learn more, visit www.waidid.org!
DNA vaccines (types, method and mechanism) Aneela Rafiq
DNA Vaccine is very promising method in current century. it can eliminate the risks of encountering pathogen with living cell.
this presentation has a brief concept about DNA Vaccine, to understand the baseline of genetic vaccine.
Update of malaria vaccines - Séances pratiques de la 4e édition du Cours international « Atelier Paludisme » - Christopher PLOWE - University of Maryland School of Medicine - Baltimore, MD 21201 USA - Cplowe@medicine.umaryland.edu
RTS,S/AS01 (RTS,S) is a malaria vaccine that has been developed through a partnership between GlaxoSmithKline Biologicals (GSK) and the PATH Malaria Vaccine Initiative (MVI), with support from the Bill & Melinda Gates Foundation and from a network of African research centers that performed the studies.
vaccine is a biological preparation that provides active acquired immunity to a particular disease. A vaccine typically contains an agent that resembles a disease-causing microorganism and is often made from weakened or killed forms of the microbe, its toxins, or one of its surface proteins. The agent stimulates the body's immune system to recognize the agent as a threat, destroy it, and to further recognize and destroy any of the microorganisms associated with that agent that it may encounter in the future.
HISTORY OF VACCINES-
EDWARD JENNER conduct experiments in 1796 that lead to the creation of the first smallpox vaccine for prevention of smallpox.
A vaccine for RABIES is developed by LOUIS PASTEUR .
Vaccine for COLERA and TYPHOID were developed in 1896 and PLAGE vaccine in 1887.
The first DIPHTHERIA vaccine is developed in about 1913 by EMIL ADOLPH BEHRING,WILLIAM HALLOCK PARK.
The whole cell PERTUSIS vaccines are developed in 1914.
A TETANUS vaccine is developed in 1927.
Developing vaccines against infectious and epidemic diseases with the aid of Bioinformatics is now possible, by predicting epitopes on an antigen and finding possible targets for the antibody to bind. A new era of vaccine production is just ahead of us.
Watch out the ppt to know more!!!
phage therapy is the use of bacteriophages to kill pathogenic bacterial cells. Bacteriophages are bacterial parasites that invade bacterial cells and engulf them like blue whale fish kills euphausiids and copepodsand in sea .
Katie Flanagan - Malaria vaccines current status and challengesWAidid
Vaccines are considered the most cost-effective means of control, prevention, elimination, eradication of infectious diseases: for this reason, a malaria vaccine would greatly assist in the drive to eradicate malaria from the world. Professor Flanagan presents in this slideset the current status and challenges of developing malaria vaccines.
To learn more, visit www.waidid.org!
DNA vaccines (types, method and mechanism) Aneela Rafiq
DNA Vaccine is very promising method in current century. it can eliminate the risks of encountering pathogen with living cell.
this presentation has a brief concept about DNA Vaccine, to understand the baseline of genetic vaccine.
Update of malaria vaccines - Séances pratiques de la 4e édition du Cours international « Atelier Paludisme » - Christopher PLOWE - University of Maryland School of Medicine - Baltimore, MD 21201 USA - Cplowe@medicine.umaryland.edu
PATH Malaria Vaccine Initiative's (MVI) presentation at the 2009 Partnering for Cures meeting in New York. MVI's mission is to accelerate the development of malaria vaccines and ensure their availability and accessibility in the developing world.
Gene Olinger, USAMRIID, Fort Detrick USA, presents at the ProImmune Antigen Characterization and Biomarker Discovery Summit, January 2011.
Protective Immune Reponses to Ebola Virus
Novel research aimed at finding a cure for AIDS requires animal models responding to human antiretroviral drugs. However, there have been few antiretrovirals cross-active against the simian viruses. In this study, we expanded the arsenal of drugs active against the simian retrovirus SIVmac251 and showed that this virus is inhibited by the protease inhibitor, darunavir, and the CCR5 blocker, maraviroc. Administration of these two drugs in combination with the reverse transcriptase inhibitors, tenofovir and emtricitabine, and the integrase inhibitor, raltegravir, resulted in prolonged plasma viral loads below assay detection limits, and, surprisingly, restricted the viral reservoir, a marker of which is viral DNA. We then decided to employ this multidrug regimen (termed “highly intensified ART”) in order to increase the potency of a previous strategy based on the gold drug auranofin, which recently proved able to restrict the viral reservoir in vivo. A short course of highly intensified ART following the previous treatment resulted, upon therapy suspension, in a remarkably spontaneous control of the infection, that may pave the way to a persistent suppression of viremia in the absence of ART. These results corroborate the robustness of the macaque AIDS model as a vanguard for potentially future treatments for HIV in humans.
Most developments in biotechnology originated for their potential applications in health care.
Contributions of biotechnology are more frequent, more notable and more rewarding in health sector.
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
Adv. biopharm. APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMSAkankshaAshtankar
MIP 201T & MPH 202T
ADVANCED BIOPHARMACEUTICS & PHARMACOKINETICS : UNIT 5
APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMS By - AKANKSHA ASHTANKAR
Knee anatomy and clinical tests 2024.pdfvimalpl1234
This includes all relevant anatomy and clinical tests compiled from standard textbooks, Campbell,netter etc..It is comprehensive and best suited for orthopaedicians and orthopaedic residents.
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
New Drug Discovery and Development .....NEHA GUPTA
The "New Drug Discovery and Development" process involves the identification, design, testing, and manufacturing of novel pharmaceutical compounds with the aim of introducing new and improved treatments for various medical conditions. This comprehensive endeavor encompasses various stages, including target identification, preclinical studies, clinical trials, regulatory approval, and post-market surveillance. It involves multidisciplinary collaboration among scientists, researchers, clinicians, regulatory experts, and pharmaceutical companies to bring innovative therapies to market and address unmet medical needs.
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
2. One of the oldest known diseases.
40% of the world’s population lives in endemic areas.
WHO, estimates that there are 350 - 500 million cases
of malaria worldwide.
1.5-2.7 million deaths (90% Africa)
Increasing problem (re-emerging disease)
resurgence in some areas
drug resistance (↑mortality)
3. Malaria kills in one year what AIDS kills in 15 years.
For every death due to HIV/AIDS there are about 50
deaths due to malaria.
4. MVI is working with the International Centre for Genetic Engineering
and Biotechnology (ICGEB) in New Delhi, India, to develop a vaccine
against Plasmodium vivax. This development effort includes Bharat
Biotech International Ltd. (Hyderabad), which will manufacture the
vaccine for preclinical testing followed by initial safety trials in adults.
5. 5
Mission: To accelerate the
development of malaria
vaccines and ensure their
availability and accessibility
in the developing world
Vision: A world free from
malaria
Goal: To develop by 2025 a
malaria vaccine with 80% or
greater efficacy that lasts
for at least four years
MVI was established in 1999 as a program of PATH,
an international nonprofit organization that creates sustainable,
culturally relevant solutions, enabling communities worldwide to
break longstanding cycles of poor health.
6. Difficult to grow in artificial medium
Mutation of parasites
Antigenic variation
Multiple antigens
Lack of suitable animal model
Lack of effective adjuvants
Lack of proven delivery system
Lack of volunteers & expense in carrying
trials
9. Stage of
plasmodium
Antigens Salient features
Pre-erythrocytic Irradiated sporozoites , Circum Sporozoite
Protein (CSP) or peptides, Liver stage
Antigens -1 (LSA-1)
Stage/species specific; antibody
blocks infection of liver; large
immunising dose required; can
abort an infection
Merozoite and
Erythrocytes
Erythrocyte Binding Antigen (EBA-175),
Merozoite Surface Antigen 1&2 (MSA-1&2)
; Ring Infected Erythrocyte Surface Antigen
(RESA); Serine Repeat Antigen (SERA);
Rhoptry Associated Protein (RAP); Histidine
Rich Protein (HRP); Apical Membrane
Antigen-1 (AMA-1)
Specific for species and stage;
Cannot abort an infection;
Prevents invasion of
erythrocytes, thus reducing
severity of infection
Gametocytes &
gametes
Pfs 25, 48/45k, Pfs 230 Prevents infection of mosquitoes;
antibody to this antigen prevents
either fertilization or maturation
of gametocytes, zygotes or
ookinetes; is of use in endemic
areas but not suited for travelers;
antibody blocks transmission
cycle
Combined vaccine
(cocktail)
SPf 66 (based on pre-erythrocytic and
asexual blood stage proteins of Pf)
Based on incorporation of
antigens from different stages
into one vaccine to produce an
immune response, blocking all
stages of the parasite
development
10. How they work:
◦ Generates Ab response against sporozoites and prevents them
from invading the liver
◦ Prevents intra-hepatic multiplication by killing parasite-infected
hepatocytes
Intended Use:
◦ Ideal for travelers - protects against malaria infection
11. How they work:
◦ Elicit antibodies that will inactivate merozoites and/or target
malarial Ag expressed on RBC surface
◦ Inhibit development of parasite in RBCs
Intended Use:
◦ Morbidity reduction in endemic countries
12. How they work:
◦ Induces Ab against sexual stage Ag
◦ Prevents development of infectious sporozoites in
salivary glands of mosquitoes
◦ Prevent or decrease transmission of parasite to new
hosts
Intended Use:
◦ Decreased malaria transmission
13. Aim: To reduce pathological consequences of infection
In highly endemic areas older children often present with high
parasitemia & little evidence of clinical disease.
TNF-α causes clinical manifestations, so vaccines directed
against TNF inducing Ags may be effective in preventing
pathological consequences.
14.
15. 1. Attenuated whole parasites
◦ Deliver a vast array of antigens
◦ Multiepitope vaccine
2. Sub-unit vaccines
◦ Polyvalent, multicomponent vaccine
◦ Targeting different protiens in different stages
◦ Recombinant antigens or long synthetic peptides
16. 1. Whole cell sporozoite vaccine
◦ Using inactivated sporozoites
◦ 1910 – avian malaria
◦ 1941- fowls
◦ 1967- mice
◦ 1970s- human volunteers
Limitation- precise irradiation
Genetically attenuated parasites
P.berghei- with deletion UIS3, UIS4, P36p
P.falciparum- with deletion of p52, p36
17. The first vaccine developed that has undergone field trials
Developed by Manuel Elkin Patarroyo in 1987.
It presents a combination of antigens from the sporozoite (using CS
repeats) and merozoite parasites.
During phase I trials a 75% efficacy rate was demonstrated and the
vaccine appeared to be well tolerated by subjects and
immunogenic.
The phase IIb and III trials were less promising, with the efficacy
falling to between 38.8% and 60.2%.
Despite the relatively long trial periods and the number of studies
carried out, it is still not known how the SPf66 vaccine confers
immunity
18. Based on the circumsporoziote protein, but additionally has
the recombinant protein covalently bound to a purified
Pseudomonas aeruginosa toxin (A9).
A complete lack of protective immunity was demonstrated in
those inoculated at early stage.
The study group used in Kenya had an 82% incidence of
parasitaemia whilst the control group only had an 89%
incidence.
Intended to elicits a cellular response enabling the
destruction of infected hepatocytes was also not observed
19. Blocks transmission of the parasite from vertebrate host to mosquitoes.
The highly attenuated NYVAC vaccinia virus strain has been utilized to
develop a multiantigen , multistage vaccine candidate for malaria.
Genes encoding seven Pf antigens derived from the
1. sporozoite (CSP and sporozoite surface protein 2),
2. Liver (liver stage antigen 1),
3. blood (merozoite surface protein 1, serine repeat antigen, and apical
membrane antigen 1),
4. sexual (Pfs25 , 25-kDa sexual-stage antigen)
inserted into a single NYVAC genome to generate NYVAC-Pf7.
safe and well tolerated.
Specific antibody responses against four of the P. falciparum antigens
were characterized during 1a clinical trial. ( CSP,PfSSP2,MSP1,Pfs25)
20. Shizont export protein (5.1)
19 repeats of sporozoite surface protein
(NANP)
Low immunogenicity
Does not contain any T-cell epitopes
21. Most recently developed recombinant vaccine
The RTS,S attempted by fusing the protein CPS with a surface
antigen from Hepatitis B, hence creating a more potent and
immunogenic vaccine.
Adjuvant- emulsion of oil in water and the added adjuvants of
monophosphoryl A & QS21
the vaccine gave 7 out of 8 volunteers challenged with P.
falciparum protective immunity
22. Removing sections of DNA from parasitic genome
Inserting into vector (plasmid,DNA viral
genome,liposomes, proteoliposomes)
When plasmid is inoculated, DNA sequence is
incorporated into host DNA
Protein synthesised- expressed on cell surface of
infected cells
Bind to HLA molecule and produce memory T-cells
23. In mosquitoes, there are proteins on the surface of
gametes and ookinets that may prove useful in
formulating a vaccine that protects mosquitoes from
infection.
Antibodies to these proteins prevent the parasite from
taking up residence in the mid-gut of mosquitoes and
forming oocysts. However, in order for such vaccines to
reach mosquitoes they must be combined with efforts
to vaccinate people living in endemic areas.
24. "It is now clear that administering the PfSPZ
Vaccine intravenously confers long-term,
sterile protection in a small number of
participants, which has not been achieved
with other current vaccine approaches," said
principal investigator of the trial Robert Seder
from National Institute of Allergy and
Infectious Diseases (NIAID), part of the US
National Institutes of Health.